News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Ferrer Receives FDA Fast Track Designation for FNP-223 to Treat Progressive Supranuclear Palsy
Wednesday, June 18, 2025Ferrer a global pharmaceutical company and certified B Corp has received Fast Track designation from the US Food and Drug Administration FDA for FNP a treatment aimed at slowing the progression
Circle Pharma Secures FDA Orphan Drug Designation for CID-078 to Treat Small Cell Lung Cancer
Tuesday, June 17, 2025Circle Pharma a clinicalstage biopharmaceutical firm focused on macrocyclebased cancer therapies has received Orphan Drug Designation ODD from the US Food and Drug Administration FDA for its investigational therapy CID for the treatment of small cell...
Teva and Fosun Pharma Form Strategic Partnership to Advance Development of TEV-56278 in Cancer Immunotherapy
Tuesday, June 17, 2025Teva Pharmaceutical Industries Ltd and Shanghai Fosun Pharmaceutical Group Co Ltd have announced a strategic collaboration through their respective subsidiaries for the development of TEV
U.S. FDA Approves UroGen’s ZUSDURI™ as First Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Friday, June 13, 2025UroGen Pharma Ltd a biopharmaceutical company focused on treatments for urothelial and rare cancers has received approval from the US Food and Drug Administration FDA for ZUSDURI mitomycin
S. FDA Expands Approval of AbbVie’s MAVYRET® for Treatment of Acute Hepatitis C
Thursday, June 12, 2025AbbVie has received approval from the US Food and Drug Administration FDA to expand the use of MAVYRET glecaprevirpibrentasvir its oral pangenotypic directacting antiviral DAA for treating adults and children aged
Chiesi Group Signs Global Licensing Deal with Key2Brain to Develop Therapies for Rare Neurological Disorders
Thursday, June 12, 2025Chiesi Group has entered a worldwide licensing agreement with KeyBrain AB to support the development of two bloodbrain barrier BBBcrossing recombinant enzyme replacement therapies ERTs targeting lysosomal storage disorders
X4 Pharmaceuticals Receives U.S. FDA Fast Track Status for Mavorixafor in Chronic Neutropenia
Wednesday, June 11, 2025X Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration FDA for its investigational treatment mavorixafor aimed at chronic neutropenia CN Mavorixafor is an oral CXCR
Salipro Biotech and Daewoong Pharmaceutical Enter Research Partnership to Develop New Therapeutics
Wednesday, June 11, 2025Salipro Biotech AB a biotechnology company based in Sweden has signed a research agreement with Daewoong Pharmaceutical Co Ltd of South Korea Through this collaboration Daewoong will access
Neowise Biotechnology Licences TCR Molecule to BeOne Medicines for Next-Generation Cell Therapy Development
Tuesday, June 10, 2025Neowise Biotechnology a company developing TCRT cell therapies targeting solid tumours has signed a nonexclusive licensing agreement with BeOne Medicines Ltd Through this collaboration
Xi Biologics Begins Construction of Microbial Manufacturing Site in Chengdu for Commercial Production
Tuesday, June 10, 2025WuXi Biologics a global Contract Research Development and Manufacturing Organisation CRDMO has commenced construction of a new microbial manufacturing site in Chengdus Wenjiang district a growing centre for pharmaceutical innovation in China
